Avamys (Fluticasone Furoate) is NOT Approved for a 1 Year 5 Month Old Child
Avamys nasal spray should not be used in a child who is 1 year and 5 months old, as it is only FDA-approved for children aged 2 years and older. 1
Age-Based Approval and Dosing
According to the American Academy of Otolaryngology-Head and Neck Surgery clinical practice guidelines, fluticasone furoate nasal spray (marketed as Veramyst in the US, Avamys internationally) has the following age restrictions:
- Minimum approved age: ≥2 years 1
- Approved dosing for ages 2-11 years: 1-2 sprays per nostril every day (27.5 µg per spray) 1
At 17 months of age (1 year 5 months), this child falls 7 months below the minimum approved age for this medication.
Alternative Options for This Age Group
For a child under 2 years old with nasal symptoms, consider these FDA-approved alternatives:
If Allergic Rhinitis is Suspected:
- Mometasone furoate (Nasonex): Approved for ≥2 years, so still not appropriate 1
- Triamcinolone acetonide (Nasacort): Approved for ≥2 years, so still not appropriate 1
The Reality:
No intranasal corticosteroids are FDA-approved for children under 2 years of age 1. The only intranasal corticosteroid with specific pediatric labeling for very young children is budesonide nebulizer suspension, which is approved for ages 1-8 years for asthma (not rhinitis) 2.
Clinical Considerations
Why the Age Restriction Exists:
- Lack of safety and efficacy data in children under 2 years
- Growth concerns: While fluticasone furoate has been studied for growth effects in older children, one study showed a small but statistically significant reduction in growth velocity (-0.27 cm/year) in prepubescent children aged 5-8 years 3
- Difficulty with administration in very young children who cannot cooperate with nasal spray technique
- Systemic absorption concerns in developing children
What to Do Instead:
For a 17-month-old with nasal symptoms:
- Establish the correct diagnosis first - viral upper respiratory infections are far more common than allergic rhinitis at this age
- Consider non-pharmacologic measures: saline nasal irrigation, humidification, allergen avoidance if allergies are confirmed
- If medication is truly needed, consult with a pediatric allergist or ENT specialist who may consider off-label use only after careful risk-benefit assessment
- Oral antihistamines may be an option for allergic symptoms, though most second-generation antihistamines are also not approved for this age group
Critical Safety Warning
Using Avamys in a child under 2 years old would be off-label use without established safety or efficacy data. This should only be considered in exceptional circumstances under close supervision by a pediatric specialist, and only after all appropriate alternatives have been exhausted.
The drug information provided in the evidence 4 appears to be for a lice treatment product, not Avamys nasal spray, and should be disregarded as irrelevant to this question.